PPARD agonists can promote cholesterol accumulation in macrophages, reduce obesity (50), increase fatty acid oxidation and oxidative phosphorylation in skeletal muscle, and increase insulin sensitivity (51). The gene discussed is PPARD; the disease is obesity due to melanocortin 4 receptor deficiency.